L6545

Letrozole

≥98% (HPLC), powder, non-steroidal aromatase inhibitor

• Sinónimos: 4,4′-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile
• Fórmula empírica (notación de Hill): C₁₇H₁₁N₅
• Número de CAS: 112809-51-5
• Peso molecular: 285.30
• Número MDL: MFCD00866241
• Código UNSPSC: 51111800
• ID de la sustancia en PubChem: 329817641
• NACRES: NA.77

Propiedades

• Nombre del producto: Letrozole, ≥98% (HPLC)
• Ensayo: ≥98% (HPLC)
• Formulario: powder
• color: white to off-white
• solubilidad: DMSO: >50 mg/mL
• emisor: Novartis
• temp. de almacenamiento: 2-8°C
• cadena SMILES: N#CC(C=C1)=CC=C1C(N2C=NC=N2)C3=CC=C(C#N)C=C3
• InChI: 1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
• Clave InChI: HPJKCIUCZWXJDR-UHFFFAOYSA-N
• Información sobre el gen: human ... CYP19A1(1588)

Descripción

Aplicación

Letrozole has been used:

• in organoid growth assay to determine its inhibitory capacity(48)
• to investigate steroid receptor coactivator-1 (SRC-1) mediated endogenous estrogen regulation of hippocampal PSD-95(49)
• to determine its effects on tumor-induced hyperalgesia(50)
• for hormonal manipulation in rats(51)
• to study its effects on lipocalin-2 (Lcn2)(52)
• to determine its effects on mechanical hyperalgesia and aromatase expression(53)

Acciones bioquímicas o fisiológicas

Letrozole acts as an adjuvant agent and is used to treat breast cancer.[1]

Letrozole is a non-steroidal aromatase inhibitor.

Letrozole is a third generation nonsteroidal aromatase inhibitor. It is a competitive inhibitor of the aromatase enzyme system and thus inhibits the conversion of androgens to estrogens. Letrozole inhibits the aromatase enzyme by competitively binding to the heme of the cytochrome P450 subunit of the enzyme, resulting in a reduction of estrogen biosynthesis in all tissues.

Características y beneficios

This compound is featured on the Nuclear Receptors (Steroids) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Pictogramas: GHS08
• Palabra de señalización: Warning
• Frases de peligro: H361fd,H373
• Consejos de prudencia: P202 - P260 - P280 - P308 + P313 - P405 - P501
• Clasificaciones de peligro: Repr. 2 - STOT RE 2
• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable